HC Wainwright & Co. Maintains Buy on VYNE Therapeutics, Lowers Price Target to $5.75
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis maintains a 'Buy' rating on VYNE Therapeutics but has lowered the price target from $28 to $5.75.
October 30, 2023 | 6:59 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Despite the lowered price target, HC Wainwright & Co. maintains a 'Buy' rating on VYNE Therapeutics, indicating continued confidence in the company.
The lowered price target could potentially indicate a perceived decrease in VYNE's future performance. However, the maintained 'Buy' rating suggests that HC Wainwright & Co. still sees potential in the company. This mixed signal could lead to uncertainty in the market, potentially keeping the stock price stable in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100